Maximilian J. Hochmair
Floridsdorf, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 161 publications
Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 28, 2026
Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung Cancer.
Journal: The New England journal of medicine
Published: June 01, 2026
SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLC.
Journal: Future oncology (London, England)
Published: April 06, 2026
Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: January 16, 2026
Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial.
Journal: Future oncology (London, England)
Published: December 18, 2025
Structured Expert Elicitation of Long-Term Survival in Non-small Cell Lung Cancer: A Case Study Applying Guidance from NICE Technical Support Document 26.
Journal: Applied health economics and health policy
Published: December 08, 2025
Clinical Impact of EGFR Mutation Subtypes on Treatment Outcomes in Advanced Non-Small Cell Lung Cancer: An Austrian Real-World Study.
Journal: Cancers
Published: November 29, 2025
Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant Non-Small Cell Lung Cancer across Treatment Lines: Evidence from the TRACER/HERTras Real-World Cohort.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: November 13, 2025
Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Mutant NSCLC Across Treatment Lines: Evidence From the TRACER/HERTras Real-World Cohort.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: November 13, 2025
Plain language summary of the ALINA study results: alectinib compared with chemotherapy after surgery in people with ALK-positive non-small cell lung cancer.
Journal: Future science OA
Published: November 11, 2025
EGFR mutation status, treatment patterns, and outcomes in resectable early-stage non-small cell lung cancer prior to adjuvant EGFR-TKI approval: An international real-world study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: October 16, 2025
Last Updated: 09/26/2026